Blood Screening Market by Product (Reagent & Kits, Instrument, Software), Technology (NAT, (Real-Time PCR), ELISA (Chemiluminescence Immunoassay), Rapid Test, Western Blot), End User (Blood Bank, Hospital), & Region - Global Forecast to 2028
The global blood screening market in terms of revenue was estimated to be worth $2.4 billion in 2023 and is poised to reach $3.4 billion by 2028, growing at a CAGR of 7.2% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The need for blood is ever-increasing, forcing the number of blood donations to rise as well throughout the world. Combining this factor along with the growing infectious diseases is the major contributor for the growing blood screening market.
On the other hand, the unfavorable reimbursement scenario and the high cost of instruments and kits may restrain the growth of this market to a certain extent.
To know about the assumptions considered for the study, Request for Free Sample Report
Blood screening Market Dynamics
Driver: Increasing number of blood donations worldwide
Advancements in healthcare systems and the availability of and the need for sophisticated surgical procedures, such as cardiovascular & transplant surgery, trauma care, and therapy for cancer and blood diseases, blood transfusions, etc has caused an increase in need for donated blood. On average, globally around 235 million major surgeries are being performed every year, of which 63 million are traumatic surgeries, cancer-related are over 31 million, and 10 million are related to pregnancy complications. Blood transfusion is usually prescribed in cases like complicated childbirths to prepare for childhood congenital maternal blood disorders, acute anemia, and trauma.
Opportunity: Emerging markets
India, the Middle East and Africa are emerging markets where players in the blood screening industry can benefit from rising disposable incomes and improved healthcare infrastructures. For example, in 2020, India’s healthcare sector was worth about USD 280 billion and is expected to grow to USD 372 billion in 2022 due to increasing income levels, growing awareness of physical well-being and rising prevalence of lifestyle diseases. Currently, ELISA is the most popular technology in India because NAT has relatively low penetration in India. In contrast, in India, NAT is not mandatory. Currently, NAT is used by nearly 120 blood banks in ID-NAT format, while around 40 blood banks use pooling technique. As a result, the Indian government has launched an initiative to educate doctors, hospitals and blood banks on the use of NAT.
Restraint: Alternative technologies
Computerized immunoassays are a one-step answer for single-particle location without requiring washing steps in view of ELISA utilizing a variety of femtoliter-sized wells. In this measure, a biomarker particle is formed with an immunizer covered with attractive microparticle cultivated in a well, enhanced by means of an enzymatic response, and distinguished with fluorescence. These tests have seen huge interest due to the earnest also, always expanding interest for serological Coronavirus counter acting agent tests that are modest, fast, straightforward, profoundly touchy, quantitative, and insignificantly obtrusive. Consequently, a solitary step, sans wash immunoassay for quick and exceptionally delicate quantitative investigation of human serological gG against SARS-CoV-2 has been created, which requires just a solitary bead of serum.
Challenge: High cost of blood screening technologies
With the increasing number of blood donations, awareness of blood verification & safety, and spending on healthcare around the world, more advanced technologies are widely used in high income countries and will be widely adopted in middle and low-income countries within the next 10 years. However, most developing countries, including India and China currently use ELISA. The growth of the market for blood screening for NAT is severely inhibited in the present timeframe. The high cost of advanced tests has led to the increased use of first-generation ELISA, which is older and less effective tests. This test is used in many countries around the world despite the limitations of the test. For example, the global donor supported cost of USD. GeneXpert MB / RIF cartridge is considered to be prohibitively expensive for most low and middle income countries (MIC).
Blood screening Ecosystem/Market Map
In 2022, reagents & kits segment accounted for the largest share of the blood screening industry, by product & service.
The blood screening market is divided into reagents and kits, tools, and software and services. Reagents and kits made up the biggest chunk of the market in 2022. This is mainly because there's been an increase in blood transfusions, which means more and more people are using reagents and kits.
In 2022, nucleic acid test segment accounted for the largest share in the blood screening industry, by technology.
The blood screening market is segmented into nucleic acid test (NAT), serology/immunoassay, rapid tests, western blot assays, and next-generation sequencing (NGS). The nucleic acid test segment dominated the blood screening market in 2022 due to an increase in adoption of NAT technology, which is more sensitive than other blood screening technologies, and an increase in the number of blood donations.
In 2022, blood banks and hospitals segment accounted for the largest share in the blood screening industry, by end user.
Blood banks and hospitals are the two main segments in the blood screening market, and the blood banks segment had the biggest market share in 2022. This is because more and more people are getting organ transplants.
North America is the largest regional market for blood screening industry
There are five main regions in the world where blood screening is available. North America is the biggest one, with a share of the market in 2022. This is due to the rising cost of healthcare, the rise in chronic conditions, and the fact that the US has a really well-developed healthcare system.
To know about the assumptions considered for the study, download the pdf brochure
The major players in this market are F. Hoffmann-La Roche Ltd. (Switzerland), Grifols (Spain), Abbott Laboratories, Inc. (US), Bio-Rad Laboratories, Inc. (US), Danaher (Beckman Coulter, Inc.) (US), bioMérieux (France), Hologic (US), Thermo Fisher Scientific, Inc. (US), Becton, Dickinson and Company (US), DiaSorin (Italy). The market leadership of these players stems from their comprehensive product portfolios and expanding global footprint. These dominant market players possess several advantages, including strong marketing and distribution networks, substantial research and development budgets, and well-established brand recognition.
Scope of the Blood Screening Industry:
|
Report Metric |
Details |
|
Market Revenue in 2023 |
$2.4 billion |
|
Estimated Value by 2028 |
$3.4 billion |
|
Revenue Rate |
Poised to grow at a CAGR of 7.2% |
|
Market Driver |
Increasing number of blood donations worldwide |
|
Market Opportunity |
Emerging markets |
This report categorizes the Blood screening market to forecast revenue and analyze trends in each of the following submarkets:
By Product & Service
-
Reagents & Kits
-
NAT Reagents & Kits
- Enzymes & Polymerases
- Standards & Controls
- Probes & Primers
- Buffers, Nucleotides, and Solutions
- Labeling & Detection Reagents
-
ELISA Reagents & Kits
- Immunosorbents
- Controls
- Conjugates
- Substrates
- Sample Diluents & Wash Solutions
- Other Reagents & Kits
-
NAT Reagents & Kits
-
Instruments
- Rental Purchase
- Outright Purchase
- Software & Services
By Technology
- Nucleic Acid Test
- Transcription-mediated Amplification
- Real-time PCR
- Serology/Immunoassay
- Chemiluminescent Immunoassays
- Fluorescent Immunoassays
- Colorimetric Immunoassays/ELISA
- Rapid Tests
- Western Blot Assays
- Next-generation Sequencing
By End User
- Blood Banks
- Hospitals
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
-
Asia Pacific
- China
- Japan
- India
- Australia
- Rest of Asia Pacific
-
Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
Recent Developments of Blood Screening Industry
- In February 2023, Thermo Fisher Scientific Inc. (US) acquired TIB Molbiol (Germany), to expand its PCR test portfolio with a wide range of assays for infectious diseases.
- In December 2021, Hologic, Inc. (US) launched Panther Trax for high-volume molecular testing.
- In May 2021, Beckmann Coulter (US) launched SARS-CoV-2 IgG.
- In September 2021, Roche Diagnostics (Switzerland) acquired TIB Molbiol Group (Germany). This acquisition will enhance Roche’s broad portfolio of molecular diagnostics solutions with a wide range of assays for infectious diseases, such as identifying SARS-CoV-2 variants.
Frequently Asked Questions (FAQ):
What is the projected market revenue value of the global blood screening market?
The global blood screening market boasts a total revenue value of $3.4 billion by 2028.
What is the estimated growth rate (CAGR) of the global blood screening market?
The global blood screening market has an estimated compound annual growth rate (CAGR) of 7.2% and a revenue size in the region of $2.4 billion in 2023.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
The objective of the study is analyzing the key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies. To track companies’ developments such as acquisitions, product launches, expansions, agreements and partnerships of the leading players, the competitive landscape of the Blood screening market to analyzes market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments the market breakdown and data triangulation were used.
The four steps involved in estimating the market size are
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.
Primary Research
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify the critical qualitative and quantitative information as well as assess prospects.
The following is a breakdown of the primary respondents:
Breakdown of Primary Participants:
Note 1: Others include sales managers, marketing managers, and product managers.
Note 2: Companies are classified into tiers based on their total revenues. As of 2022, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = <USD 10 million.
To know about the assumptions considered for the study, download the pdf brochure
| COMPANY NAME |
DESIGNATION |
|
Abbott |
Marketing Manager |
|
F. Hoffmann-La Roche Ltd |
Senior Product Manager |
|
Danaher |
Marketing Manager |
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the Blood screening market's total size. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry have been identified through extensive secondary research
- The revenues generated by leading players operating in the Blood screening market have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Global Blood screening Market Size: Bottom-Up Approach
To know about the assumptions considered for the study, Request for Free Sample Report
Global Blood Screening Market Size: Top-Down Approach
Data Triangulation
After arriving at the overall market size applying the process mentioned above, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Blood screening is a medical process wherein donated blood is mainly tested for HIV1, HIV2, HBV, HCV, malaria, syphilis, and other infectious diseases. Donated blood is screened for these infectious diseases to reduce the risk of transfusion-transmissible infections (TTIs).
Key Stakeholders
- Senior Management
- End User
- Finance/Procurement Department
- R&D Department
Report Objectives
- To define, describe, segment, and forecast the global Blood screening market, by products & service, technology, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall Blood screening market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies2
- To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
- To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business and product excellence
Available Customizations
MarketsandMarkets offers the following customizations for this market report
Country Information
- Additional country-level analysis of the Blood screening market
Company profiles
- Additional five company profiles of players operating in the Blood screening market.
Product Analysis
- Product matrix, which provides a detailed comparison of the product portfolio of each company in the Blood screening market
Generating Response ...
Growth opportunities and latent adjacency in Blood Screening Market
1) We would like to mention that total market size of NAT in Germany (60.8 million in 2015), Europe and US and even others remains the same. However, contribution of RTPCR and TMA will differ. We have done that correction in the report and are sharing the updated report with you in a few minutes. However, we will conduct some further primary interviews to re-validate this data. After re-validation, if any changes/discrepancies found in the further research, we share another version if needed. 2) (NAT) includes overall molecular diagnostics products (Reagents, kits, Instruments (Analysers), Software and Services) used for the blood screening test by all type of end users such as Hospitals and Blood Banks. This number (USD 66.6 million in 2016) is largely sum of TMA and PCR based NAT testing used for blood screening. These tests are being used by blood banks and hospitals. According to WHO report (published in 2016), in 2013, there were around 70 blood centres in Germany. 3) We have identified Ortho Clinical Diagnostics as a leading player. But it will not come in top 5 players. On the basis of our analysis and product offerings we have listed it in top 10 companies (at 6th position).
What are the challenges faced by the key players of the Blood Screening Market?
Which of the segments of Blood Screening Market is expected to hold the major share?
How the technological innovations are boosting the global growth of Blood Screening Market?